4 completed, 3 recruiting, 1 active not recruiting, 1 enrolling by invitation. 4 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 4 | Recruiting 2, Not yet recruiting 1, Terminated 1 |
| Not applicable | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Completed 1 |
Follow Factor VII Deficiency: new trials by email Literature Review of Factor VII Deficiency trials Research Report on Factor VII Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency SR604 - Factor VII Deficiency | Phase 2 | Not yet recruiting | Shanghai RAAS Blood Products Co., Ltd. | 12 | 2026-07-01 | 2026-07-17 |
| A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency Sutacimig - Congenital Factor VII Deficiency | Phase 2 | Recruiting | Hemab ApS | 18 | 2026-03-11 | 2026-07-22 |
| Palliative Care Needs of Children With Rare Diseases and Their Families Family Centered pediatric palliative care for family caregivers of children with rare diseases. - Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia | Not applicable | Enrolling by invitation | Children's National Research Institute | 480 | 2025-10-02 | 2026-01-28 |
| An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency SR604 - Hemophilia A, Hemophilia B | Phase 1 / Phase 2 | Recruiting | Shanghai RAAS Blood Products Co., Ltd. | 76 | 2024-05-31 | 2026-06-12 |
| A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) SR604, Placebo - Healthy Participants, Hemophilia A | Phase 1 | Recruiting | Equilibra Bioscience LLC | 31 | 2024-05-10 | 2026-07-02 |
| A Phase I of SS109 in Hemophilia A or and B With Inhibitors SS109 - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 27 | 2022-12-14 | 2023-08-22 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| Early Check: Expanded Screening in Newborns Confirmatory Testing - Spinal Muscular Atrophy, Fragile X Syndrome | Active not recruiting | RTI International | 30000 | 2018-10-15 | 2026-07-01 | |
| Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Eptacog alfa, biosimilar, Novoseven - Factor VII Deficiency | Phase 3 | Completed | AryoGen Pharmed Co. | 24 | 2017-03-01 | 2021-02-04 |
| Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Completed | AryoGen Pharmed Co. | 200 | 2016-06-13 | 2022-02-15 | |
| Treatment of Inherited Factor VII Deficiency plasma derived Factor VII, recombinant FVIIa, Fresh Frozen Plasma - Factor VII Deficiency | Completed | University of L'Aquila | 223 | 2007-01-01 | 2012-11-27 |
Hemophilia A (4) · Hemophilia B (3) · Thrombasthenia (2) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1) · 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (1) · 3-methylcrotonyl CoA carboxylase 1 deficiency (1) · 3-methylcrotonyl CoA carboxylase 2 deficiency (1) · Acidemia, isovaleric (1) · Acrodermatitis enteropathica (1) · Adenine phosphoribosyltransferase deficiency (1) · Adrenal hyperplasia, congenital, type 5 (1) · Adrenocorticotropic hormone deficiency (1) · Amaurosis congenita of Leber, type 2 (1) · Anemia, Sickle Cell (1)
Blood Coagulation Disorders (11) · Blood Coagulation Disorders, Inherited (11) · Coagulation Protein Disorders (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Hemorrhagic Disorders (11) · Blood Platelet Disorders (3) · Genetic Diseases, X-Linked (3) · Abnormalities, Multiple (2) · Bone Diseases (2) · Bone Diseases, Developmental (2) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2)
recombinant FVIIa (2) · Biosimilar Pharmaceuticals (1) · Factor VII (1)
AryoGen Pharmed Co. (2) · Shanghai RAAS Blood Products Co., Ltd. (2) · Catalyst Biosciences (1) · Children's National Research Institute (1) · Equilibra Bioscience LLC (1) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (1) · Hemab ApS (1) · RTI International (1) · University of L'Aquila (1)
United States (4) · China (3) · Iran (2) · Italy (2) · Canada (1) · India (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Curt Scharfe, MD, PhD (1) · Massimo Iacobelli, MD (1) · Maureen E Lyon, PhD (1) · Mohammad Faranoush, MD (1) · Renchi Yang (1)
PMID 23403322, PMID 24763923, PMID 31315600, PMID 35142618
R01HD117137 (1)